Eyenovia, INC 8-K filings

Eyenovia stockholders approved a reverse stock split, an increase in shares for the stock incentive plan, and the potential issuance of shares upon exercise of purchase warrants at a special meeting held on January 21, 2025.

Eyenovia, Inc. has repriced existing warrants, leading to the immediate exercise of these warrants and the issuance of new warrants, generating approximately $1 million in gross proceeds.

Eyenovia, Inc. has amended its at-the-market offering agreement, replacing Leerink Partners with Chardan Capital Markets as the sales agent for up to $50 million in common stock.

Eyenovia, Inc. has received a delisting notice from Nasdaq due to its stock price falling below $0.10, and is planning an appeal and a reverse stock split to regain compliance.

Eyenovia, Inc. has announced a registered direct offering expected to generate approximately $1.9 million to support working capital, debt repayment, and the development of its Optejet device.

Eyenovia, Inc. has announced a registered direct offering to raise approximately $1.3 million through the sale of common stock and warrants.

Eyenovia, Inc. has amended its loan agreement to defer payments and issued shares to lenders, while also seeing a change in its CFO role.

Eyenovia, Inc. reports a cash balance of $0.7 million and is in discussions to restructure its $10.1 million debt with Avenue Capital Management while also considering strategic alternatives.

Eyenovia's Phase 3 CHAPERONE study failed to meet its primary efficacy endpoint, leading to a strategic review, workforce reduction, and potential business restructuring.

Eyenovia reported its third quarter 2024 financial results, highlighted by the U.S. launch of a new ocular steroid and progress in its myopia and dry eye programs.

Eyenovia, Inc. has announced a registered direct offering expected to raise approximately $4 million to support commercialization efforts and clinical studies.

Eyenovia, Inc. has received a notice from Nasdaq that its stock price has fallen below the minimum $1.00 per share requirement for continued listing.

Eyenovia, Inc. has appointed Andrew Jones as its new Chief Financial Officer, succeeding John Gandolfo who is retiring but will remain with the company for a transition period.

Eyenovia is set to launch Mydcombi and Clobetasol in the near term, while also progressing its MicroPine program for pediatric myopia.

Eyenovia, Inc. has agreed to sell 12,850,000 shares of common stock at $0.40 per share, raising approximately $5.14 million to support product commercialization and a clinical study.

Eyenovia announced its second quarter 2024 financial results, highlighting progress in commercialization, product development, and strategic collaborations.

Eyenovia, Inc. has successfully regained compliance with Nasdaq's minimum bid price requirement after its stock price closed above $1.00 for ten consecutive business days.

Eyenovia, Inc. has received a notice from Nasdaq that its stock price has fallen below the minimum $1.00 per share requirement for continued listing.

Eyenovia, Inc. has announced a registered direct offering expected to raise approximately $5 million to fund commercialization efforts, clinical studies, and general corporate purposes.

Eyenovia, Inc. has increased its authorized common stock shares from 90 million to 300 million and held its 2024 Annual Meeting of Stockholders.

Eyenovia, Inc. released an updated corporate presentation on June 4, 2024, detailing its commercial progress, pipeline advancements, and market opportunities.

Eyenovia, Inc. is resuming its at-the-market offering of common stock after a temporary suspension, filing a new prospectus supplement and legal opinion.

Eyenovia announced its first quarter 2024 financial results, highlighted by progress in its MicroPine myopia program and the upcoming launch of clobetasol for post-surgical inflammation.

Eyenovia, Inc. has filed a prospectus supplement to register the sale of 3,223,726 shares of its common stock.

Eyenovia, Inc. has entered into a securities purchase agreement for a registered direct offering, raising approximately $2 million to support product commercialization, a clinical study, and general corporate needs.

Eyenovia, Inc. has suspended its at-the-market (ATM) offering and is exploring strategic options to enhance shareholder value, while also accelerating development of its MicroPine product.

Eyenovia, Inc. has released an updated corporate presentation detailing its progress in ophthalmic therapeutics, including the launch of MydCombi and Clobetasol, and advancements in its pipeline.

Eyenovia has amended its previous 8-K filing to update its investor presentation, clarifying market size opportunities and the cost of an NDA filing for Apersure.

Eyenovia released an updated investor presentation detailing progress on its ophthalmic drug pipeline, including the commercial launch of Mydcombi, upcoming FDA decision for APP13007, and the reacquisition of MicroPine development rights.

Eyenovia has reacquired the rights to MicroPine, a potential treatment for pediatric progressive myopia, from Bausch + Lomb, strengthening its late-stage drug portfolio.